company background image
1786

SciVision BiotechTWSE:1786 Stock Report

Market Cap

NT$3.3b

7D

-0.5%

1Y

-21.4%

Updated

23 Sep, 2021

Data

Company Financials
1786 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends1/6

1786 Overview

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan.

Price History & Performance

Summary of all time highs, changes and price drops for SciVision Biotech
Historical stock prices
Current Share PriceNT$54.60
52 Week HighNT$45.80
52 Week LowNT$73.20
Beta0.50
1 Month Change-3.19%
3 Month Change1.49%
1 Year Change-21.44%
3 Year Change-24.37%
5 Year Change-2.17%
Change since IPO66.73%

Recent News & Updates

Apr 20
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Apr 02
SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...

Mar 15
Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

We believe investing is smart because history shows that stock markets go higher in the long term. But if you choose...

Shareholder Returns

1786TW Medical EquipmentTW Market
7D-0.5%-0.2%-1.0%
1Y-21.4%10.8%39.0%

Return vs Industry: 1786 underperformed the TW Medical Equipment industry which returned 5.3% over the past year.

Return vs Market: 1786 underperformed the TW Market which returned 34% over the past year.

Price Volatility

Is 1786's price volatile compared to industry and market?
1786 volatility
1786 Beta0.50
Industry Beta0.93
Market Beta1

Stable Share Price: 1786 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 1786's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aTai Xian Hanhttps://www.scivision.com.tw

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.

SciVision Biotech Fundamentals Summary

How do SciVision Biotech's earnings and revenue compare to its market cap?
1786 fundamental statistics
Market CapNT$3.33b
Earnings (TTM)NT$125.57m
Revenue (TTM)NT$490.92m

26.5x

P/E Ratio

6.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1786 income statement (TTM)
RevenueNT$490.92m
Cost of RevenueNT$135.09m
Gross ProfitNT$355.83m
ExpensesNT$230.26m
EarningsNT$125.57m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.06
Gross Margin72.48%
Net Profit Margin25.58%
Debt/Equity Ratio41.1%

How did 1786 perform over the long term?

See historical performance and comparison

Valuation

Is SciVision Biotech undervalued compared to its fair value and its price relative to the market?

26.53x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1786 (NT$54.6) is trading above our estimate of fair value (NT$20.56)

Significantly Below Fair Value: 1786 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1786 is poor value based on its PE Ratio (26.5x) compared to the TW Medical Equipment industry average (23.1x).

PE vs Market: 1786 is poor value based on its PE Ratio (26.5x) compared to the TW market (16.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1786's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1786 is overvalued based on its PB Ratio (2.3x) compared to the TW Medical Equipment industry average (2x).


Future Growth

How is SciVision Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SciVision Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has SciVision Biotech performed over the past 5 years?

45.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1786 has high quality earnings.

Growing Profit Margin: 1786's current net profit margins (25.6%) are lower than last year (27.8%).


Past Earnings Growth Analysis

Earnings Trend: 1786's earnings have grown significantly by 45.1% per year over the past 5 years.

Accelerating Growth: 1786's earnings growth over the past year (1.1%) is below its 5-year average (45.1% per year).

Earnings vs Industry: 1786 earnings growth over the past year (1.1%) underperformed the Medical Equipment industry 9.5%.


Return on Equity

High ROE: 1786's Return on Equity (8.6%) is considered low.


Financial Health

How is SciVision Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: 1786's short term assets (NT$867.3M) exceed its short term liabilities (NT$421.9M).

Long Term Liabilities: 1786's short term assets (NT$867.3M) exceed its long term liabilities (NT$398.2M).


Debt to Equity History and Analysis

Debt Level: 1786's debt to equity ratio (41.1%) is considered high.

Reducing Debt: 1786's debt to equity ratio has increased from 26.3% to 41.1% over the past 5 years.

Debt Coverage: 1786's debt is well covered by operating cash flow (21.5%).

Interest Coverage: 1786's interest payments on its debt are well covered by EBIT (22.1x coverage).


Balance Sheet


Dividend

What is SciVision Biotech current dividend yield, its reliability and sustainability?

1.76%

Current Dividend Yield


Upcoming Dividend Payment

TodaySep 24 2021Ex Dividend DateOct 04 2021Dividend Pay DateOct 29 202125 days from Ex DividendBuy in the next 10 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 1786's dividend (1.76%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.96%).

High Dividend: 1786's dividend (1.76%) is low compared to the top 25% of dividend payers in the TW market (5.31%).


Stability and Growth of Payments

Stable Dividend: 1786 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 1786's dividend payments have increased, but the company has only paid a dividend for 5 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (46.6%), 1786's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Tai Xian Han

no data

Tenure

Tai Xian Han serves as a General Manager of Scivision Biotech Inc and serves as its Director.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

SciVision Biotech Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: SciVision Biotech Inc.
  • Ticker: 1786
  • Exchange: TWSE
  • Founded: 2001
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: NT$3.331b
  • Shares outstanding: 61.01m
  • Website: https://www.scivision.com.tw

Location

  • SciVision Biotech Inc.
  • 9, South 6th Road
  • K.E.P.Z.
  • Kaohsiung
  • 806011
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 16:02
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.